Recent Posts

Pleased by the FDA’s acceptance of our IND for CLS-AX (axitinib injectable suspe…

Pleased by the FDA’s acceptance of our IND for CLS-AX (axitinib injectable suspension), enabling initiation of a Phase 1/2a clinical trial in neovascular AMD by the end of 2020! Our related recently-published ARVO abstract: https://t.co/tR0Wd8yueY #retina #biotech #medicine https://t.co/WiTT8ziDgs Source by Thomas Ciulla, MD, MBA […]

RT @ThomasCiullaMD: Recently published…Diabetic macular edema, a leading cause…

RT @ThomasCiullaMD: Recently published…Diabetic macular edema, a leading cause of vision loss, is treated less intensely and shows worse… Source by Thomas Ciulla, MD, MBA Return to main website.

At the American Society of Retina Specialists meeting, our team & colleagues had…


At the American Society of Retina Specialists meeting, our team & colleagues had numerous presentations on #retina clinical science as well as #suprachoroidal delivery of tyrosine kinase inhibitor, complement Inhibitor & corticosteroid.
#biotech #medicine #clinicalresearch


Source by Thomas Ciulla, MD, MBA

Return to main website.

RT @Ophthalmologymg: Update on gene therapy: Ocular gene therapy research has sh…

RT @Ophthalmologymg: Update on gene therapy: Ocular gene therapy research has shown tremendous growth over recent years. This article discu… Source by Thomas Ciulla, MD, MBA Return to main website.

Our study has generated much interest in #Luxturna #genetherapy #healtheconomics…

Our study has generated much interest in #Luxturna #genetherapy #healtheconomics: Cost-effectiveness of Voretigene Neparvovec-rzyl vs Standard Care for RPE65-Mediated Retinal Disease https://t.co/3DeMpzCgRq via @JAMAOphth part of @JAMANetwork Source by Thomas Ciulla, MD, MBA Return to main website.

RT @ThomasCiullaMD: Recently co-authored “Update on gene therapy: A discussion o…


RT @ThomasCiullaMD: Recently co-authored “Update on gene therapy: A discussion of strategies, optimization, alternatives and administration…


Source by Thomas Ciulla, MD, MBA

Return to main website.

RT @VestrumHealth: …

RT @VestrumHealth: https://t.co/On63W7xSpL Source by Thomas Ciulla, MD, MBA Return to main website.

RT @OTEurope: How DME patients may fare differently in ‘real world’ versus trial…

RT @OTEurope: How DME patients may fare differently in ‘real world’ versus trials https://t.co/37omb0jo7P https://t.co/mWVlEnaB0Q Source by Thomas Ciulla, MD, MBA Return to main website.

RT @ViralKansaraPhD: I had the privilege of being a part of the research where m…


RT @ViralKansaraPhD: I had the privilege of being a part of the research where my colleagues and I examined the “biofactory approach” in #G…


Source by Thomas Ciulla, MD, MBA

Return to main website.

Recently co-authored “Update on gene therapy: A discussion of strategies, optimi…

Recently co-authored “Update on gene therapy: A discussion of strategies, optimization, alternatives and administration”, in Ophthalmology Management’s “Future of Retinal Care” issue… #genetherapy #ophthalmology #amd #diabetes #retina #eyes https://t.co/bXNWa4p7G0 Source by Thomas Ciulla, MD, MBA Return to main website.